Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance).

"Conflict of Interest Disclosures Ronald C. Chen has acted as a paid consultant for Accuray Inc, AbbVie, and Bayer for work performed outside of the current study. Toni K. Choueiri has received grants, personal fees, nonfinancial support, and other support from Bristol‐Myers Squibb, Exelixis Inc, and Pfizer for work performed as part of the current study and has received personal fees for advisory boards, consultation, article preparation, and travel/lodging and clinical trial grants from AstraZeneca, Bristol‐Myers Squibb, Eisai, EMD Serono Exelixis Inc, GlaxoSmithKline, Lilly, Merck, Novartis, and Pfizer for work performed outside of the current study; holds stock in Pionyr and Tempest; and sits on the National Comprehensive Cancer Network kidney panel. In addition, his institution (Dana‐Farber Cancer Institute) may have received additional independent funding from drug companies or/and royalties potentially involved in research around the subject matter. Marion Feuilly and Florence Marteau are employees of Ipsen, which was a sponsor of the current study. Jie Meng and Johanna Lister are employees of Analytica Laser, a Certara company that has received consulting fees from Ipsen Pharma SAS. Michael J. Morris has acted as a member of the advisory boards for Advanced Accelerator Applications, Astellas Pharma, Bayer, Johnson and Johnson and Progenics, for which he has received no compensation; has received research support from Progenics; has received personal fees from Curium and ORIC Pharmaceuticals; and has received research support from Endocyte for work performed outside of the current study. Aaron D. Falchook made no disclosures. Daniel J. George has received grants from Acerta Pharmaceuticals; has acted as a senior editor for the American Association for Cancer Research; has received grants from and acted as a paid consultant for Astellas Pharma; has acted as a paid consultant for AstraZeneca; has received personal fees from Axess Oncology; has received grants, personal fees, and nonfinancial support from Bayer H/C Pharmaceuticals; has received grants and personal fees from Bristol‐Myers Squibb; has received grants from Calithera; has received grants from Capio Biosciences; has received personal fees from EMD Serono; has received grants, personal fees, and nonfinancial support from Exelixis Inc; has acted as a paid consultant for Flatiron, Merck Sharp & Dohme, Michael J Hennessey Associates, Myovant Sciences Inc, Physician Education Resource, Vizuri Health Sciences, and Platform Q; has received personal fees from Ipsen; has received grants and personal fees from Janssen Pharmaceuticals and Novartis and Pfizer; has received personal fees from Millennium Medical Publishing, Modra Pharmaceuticals B.V., NCI Genitourinary, and Nektar Therapeutics; has received grants, personal fees, and nonfinancial support from Sanofi; has received personal fees from UroGPO; has received personal fees and nonfinancial support from UroToday; has received personal fees from Acceleron Pharma Inc, BioPharm, Celgene, Dendreon, Genentech, GlaxoSmithKline, Innocrin Pharma, Medivation, Merck, and Genzyme; and has received research funding from Dendreon, Genentech, Innocrin Pharma, and Millennium for work performed outside of the current study. Darren R. Feldman has received NIH P30 Cancer Center Support Grant P30 CA008748 for work performed as part of the current study and has received research funding from Astellas, Novartis, Seattle Genetics, and Decibel and royalties from UpToDate for work performed outside of the current study. Aaron D. Falchook made no disclosures."

"We thank all the patients involved in the current study as well as their caregivers and the investigators and research staff at the participating institutions. We thank Isabelle Kaufmann, PhD, of Oxford PharmaGenesis (Oxford, UK) for providing medical writing support, which was sponsored by Ipsen in accordance with Good Publication Practice guidelines."